<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261467</url>
  </required_header>
  <id_info>
    <org_study_id>191622-142</org_study_id>
    <secondary_id>2014-001860-36</secondary_id>
    <nct_id>NCT02261467</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Forehead and Glabellar Facial Rhytides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of onabotulinumtoxinA in subjects with forehead and
      glabellar facial rhytides (frown lines).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects with at Least a 2-Grade Improvement from Baseline in Forehead Line Severity at Maximum Eyebrow Elevation as Assessed by both the Investigator and Subject on the 4-Point Facial Wrinkle Scale (FWS)</measure>
    <time_frame>Baseline, Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Drug Effect for Subjects Who Receive Clinical Benefit at Day 30 Using the 4-Point Facial Wrinkle Scale (FWS)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with a Rating of None or Mild for Forehead Lines at Maximum Elevation on the 4-Point FWS Assessed by the Investigator</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reporting Treatment Satisfaction on the 5-Point Facial Line Satisfaction Questionnaire (FLSQ)</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with ≥20-Point Improvement from Baseline on the Impact Domain of the FLSQ</measure>
    <time_frame>Baseline, Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with a ≥3-Point Improvement from Baseline on Items 1, 4, and 5 of the 11-Point Facial Line Outcomes (FLO-11) Questionnaire©</measure>
    <time_frame>Baseline, Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">421</enrollment>
  <condition>Forehead Rhytides</condition>
  <condition>Glabellar Rhytides</condition>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (normal saline) followed by OnabotulinumtoxinA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA into the protocol-specified areas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OnabotulinumtoxinA</intervention_name>
    <description>OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.</description>
    <arm_group_label>OnabotulinumtoxinA</arm_group_label>
    <other_name>BOTOX® Cosmetic</other_name>
    <other_name>botulinum toxin Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo (normal saline) injected into the protocol-specified areas on Day 1.</description>
    <arm_group_label>Placebo (normal saline) followed by OnabotulinumtoxinA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe forehead and glabellar lines

          -  Willing to have facial photos taken

        Exclusion Criteria:

          -  Prior exposure to botulinum toxin of any serotype for any indication

          -  Anticipated need for treatment with botulinum toxin of any serotype for any
             indication during the study, other than study treatment

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral
             sclerosis

          -  Any facial resurfacing laser or light treatment, microdermabrasion, or superficial
             peels in the past 3 months

          -  Any medium depth or deep depth facial chemical peels; facial skin resurfacing; or
             permanent facial make-up in the past 6 months

          -  Any nonpermanent soft tissue fillers, or treatment with oral retinoids in the past
             year

          -  Prior face lift, thread lift, eyebrow lift, or related procedures (eg, eyelid and/or
             eyebrow surgery)

          -  Prior facial treatment with permanent soft tissue fillers, synthetic implants (eg,
             Gore-Tex®), and/or fat transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>October 3, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>June 3, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
